Pioglitazone – New contra-indications and warnings following European review of bladder cancer risk (Actos, Glustin, Competact, Glubrava, Tandemact) Pioglitazone belongs to the class of medicines known as ‘thiazolidinediones’ and is used in the treatment of type 2 diabetes as second-line therapy (see Summary of Product Characteristics for licensed indications). Pioglitazone (Actos and Glustin) was first [...]
New Study highlights inadequate monitoring for metabolic side-effects of antipsychotic medication New research demonstrates that patients with mental illness prescribed antipsychotic medication are not offered adequate monitoring for metabolic complications.1 Patients treated with antipsychotic medication, especially those with schizophrenia, have a high rate of metabolic problems, including: Lipid abnormalities (60%) High blood pressure (40%) Metabolic [...]
People presenting with memory problems and mild dementia are often not diagnosed promptly in primary care. New research demonstrates that general practitioners (GPs) have difficulty in correctly identifying people in the early stages of dementia.1 This results in both missed cases (false negatives) and misidentifications (false positives). Researchers from the University of Leicester, UK, the [...]
Mild cognitive impairment (MCI) is an intermediate state of cognitive function between the changes seen in ageing and those characteristics of dementia and often Alzheimer’s disease. Only a minority of people, perhaps 1 in 100, go through life with virtually no cognitive decline. Most people gradually undergo a minor cognitive decline which, although it may [...]
New findings presented at AAIC 2011 New research reported at the 2011 Alzheimer’s Association International Conference (AAIC), the world’s largest conference of its kind, offers insight on the global incidence and prevalence of mild cognitive impairment (MCI). Based on the results of six studies conducted in six different countries, the research underscores the global importance [...]
Overview of MMSE Questions* —————————————————————————————————-——————- Orientation • Time: Year/season/month/day/date (5) • Place: Country/county/town/street/floor (5) Registration • Repeat names of three objects (examiner should name three common objects) (3) Attention and Calculation • Serial 7s (93, 86, 79…) or spell ‘world’ backwards (5) Recall • Repeat the three objects mentioned before (3) Language • Name two [...]
————————————————————————————————— Orientation • Name, address, current location (street or building), city, county, date (day), month, year (8) Digit span – Present 1/sec, starting at 5 up to 7; record longest correct span • 5-1-3-9-4, 2-6-1-9-4-7, 2-1-5-4-3-7-2 (7) Immediate Recall – Number of words learned (N); number of trials needed to learn all four words up [...]
Download questionnaire as PDF (65KB) In the past 4 weeks, did the patient have any difficulty or need help with: Writing checks, paying bills, or keeping financial records Assembling tax records, business affairs, or papers Shopping alone for clothes, household necessities, or groceries Playing a game of skill or working on a hobby Heating water, [...]
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Cefuroxime 250mg, 500mg. Description: Light blue film-coated, capsule shaped tablets marked with strength on one side and P125 and P126, respectively, on the other. Presentations: 250mg-14, 500mg-14. Prices available upon request. Indications: Treatment of mild to moderately severe infections caused by cefuroxime susceptible [...]
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Cefuroxime 750mg, 1.5g. Description: Powder for solution for injection (750mg) and injection/infusion (1.5g). Presentations: 750mg, 1.5g. Prices available upon request. Indications: Treatment of infections caused by cefuroxime susceptible organisms, such as respiratory tract infections (acute exacerbation of chronic bronchitis, hospital acquired pneumonia, severe [...]
Loading ...
